Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin
Zehender, M.; Meinertz, T.; Hohnloser, S.; Geibel, A.; Hartung, J.; Seiler, K.U.; Just, H.; M, E.N.D.E.R. M.
Clin. Physiol. Biochem 8: 90-100
1990
ISSN/ISBN: 0252-1164
Accession: 075879565
PDF emailed within 1 workday: $29.90
Related References
Zehender, M.; Meinertz, T.; Hohnloser, S.; Geibel, A.; Hartung, J.; Seiler, K.U.; Just, H. 1990: Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin. Multicenter Ketanserin Research Group Clinical Physiology and Biochemistry 8(Suppl 3): 90-100Zehender, M.; Meinertz, T.; Hohnloser, S.; Geibel, A.; Hartung, J.; Seiler, K.U.; Just, H. 1989: Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin American Journal of Cardiology 63(12): 826-832
Zehender, M.; Meinertz, T.; Hohnloser, S.; Geibel, A.; Hartung, J.; Seiler K U.; Just, H.; Multicent Ketanserin Res Group 1990: Incidence and clinical relevance of qt prolongation caused by the new selective antagonist ketanserin Clinical Physiology and Biochemistry 8(Suppl 3): 90-100
Zehender, M.; Meinertz, T.; Hohnloser, S.; Geibel, A.; Hartung, J.; Seiler, K.U.; Just, H. 1989: Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserim The American Journal of Cardiology 63(12): 826-832
1982: Ketanserin: a selective serotonin antagonist Lancet 2(8303): 859
Awouters, F. 1985: The pharmacology of ketanserin, the first selective serotonin S2-antagonist Drug Development Research 6(4): 263-300
Nielsen, L.H.; Knudsen, F.; Olesen, A.S. 1990: Use of ketanserin in anesthesia. a selective S2 serotonin receptor antagonist Ugeskrift for Laeger 152(23): 1653-1655
Berridge, M.; Comar, D.; Crouzel, C.; Baron J C. 1983: Carbon 14 labeled ketanserin a selective serotonin s 2 antagonist Journal of Labelled Compounds and Radiopharmaceuticals 20(1): 73-78
Dormandy, J.A.; Berent, A.; Downes, S.J. 1988: The use of the selective serotonin S2 receptor antagonist Ketanserin in the treatment of Raynaud's phenomenon European Journal of Vascular Surgery 2(6): 371-375
Winther, K. 1985: Ketanserin a Selective Serotonin Antagonist, in Relation to Platelet Aggregation and Migraine Attack Rate Cephalalgia 5(3_Suppl): 402-403
Wenting, G. J.; Veld, A. J. Man In 'T; Woittiez, A. J.; Boomsma, F.; Schalekamp, M. A. D. H. 1982: Haemodynamic Effects of Ketanserin, a Selective 5-Hydroxytryptamine (Serotonin) Receptor Antagonist, in Essential Hypertension Clinical Science 63(S8): 435s-438s
Meloni, F.; Transi, M.G.; Sciacca, V.; De Felice, C.; Bagarone, A.; Sciacca, A. 1987: Therapeutic efficacy of ketanserin, a selective antagonist of the serotonin (5-HT2) receptors, in primary and secondary Raynaud's phenomenon Angiology 38(7): 530-536
Schalekamp, M.A.D.H. 1982: Hemodynamic effects of ketanserin a selective 5 hydroxy tryptamine serotonin receptor antagonist in essential hypertension Clinical Science (london)ppl. 8): 435s-438s
Distler, A. 1990: Clinical aspects during therapy with the serotonin antagonist ketanserin Clinical Physiology and Biochemistry 8(Suppl 3): 64-80
Shih H C. 1988: Pharmacological studies on selective serotonin s 2 antagonist antihypertensive effect of ketanserin and effects on the central nervous system Journal of Tokyo Medical College 46(5): 851-861